Sai Parenteral acquires stake in Australian pharma firm for ₹125 crore

IPO-bound pharmaceutical formulations institution Sai Parenteral’s has acquired 74.6% involvement successful Adelaide-based Noumed Pharmaceuticals for ₹125 crore.

With AUD 60 cardinal successful revenue, Noumed is simply a supplier of backstage statement over-the-counter (OTC) products to pharmacy chains crossed Australia and New Zealand. It is establishing a AUD 53 cardinal manufacturing installation successful Adelaide, which is expected to statesman commercialized operations by the 4th fourth of 2026.

With a portfolio of implicit 451 merchandise dossiers, Noumed offers important breadth crossed therapeutic categories, Sai Parenteral said connected Monday successful a merchandise connected the acquisition.

This acquisition is successful enactment with Sai Parenteral’s aspirations to go a global, innovation-led formulations and CDMO platform. “This concern enhances our introduction into semi-regulated and regulated markets with a wider, much competitory merchandise portfolio, Managing Director Anil KK said.

Sai Parenterals had filed DRHP with SEBI, for archetypal nationalist offering, successful September 30. The IPO volition comprise a caller contented of up to ₹285 crore and an connection for merchantability of up to 35 lakh shares by existing shareholders.

“Having worked with Sai Parenteral’s for a sizeable time, we are assured that unneurotic we tin accelerate our merchandise pipeline, payment from Sai’s manufacturing capabilities and conscionable increasing request successful the Australian, New Zealand and planetary markets,” Noumed managing manager Mark Thulborne said.